Adam Grzegorz Michalski

Dr. Adam Grzegorz Michalski

Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
Jacek BajJacek Baj
Jacek Baj
AFAlicja Forma
Alicja Forma
WFWojciech Flieger
Wojciech Flieger
IMIzabela Morawska
Izabela Morawska
AMAdam Grzegorz Michalski
Adam Grzegorz Michalski
GTGrzegorz Teresinski
Grzegorz Teresinski
Helicobacter pylori (H. pylori) is most known to cause a wide spectrum of gastrointestinal impairments; however, an increasing number of studies indicates that H. pylori infection might be involved in numerous extragastric diseases such as neurological, dermatological, hematologic, ocular, cardiovascular, metabolic, hepatobiliary, or even allergic diseases. In this review, we focused on the nervous system and aimed to summarize the findings regarding H. pylori infection and its involvement in the induction/progression of neurological disorders. Neurological impairments induced by H. pylori infection are primarily due to impairments in the gut–brain axis (GBA) and to an altered gut microbiota facilitated by H. pylori colonization. Currently, regarding a potential relationship between Helicobacter infection and neurological disorders, most of the studies are mainly focused on H. pylori.

14 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
KSKatarzyna Szklener
Katarzyna Szklener
AMAdam Grzegorz Michalski
Adam Grzegorz Michalski
KŻKlaudia Żak
Klaudia Żak
MPMichał Piwoński
Michał Piwoński
SMSławomir Mandziuk
Sławomir Mandziuk
Bruton’s Tyrosine Kinase (BTK) is considered crucial in the activation and survival of both physiological and malignant B-cells. In recent years, ibrutinib, an oral BTK inhibitor, became a breakthrough therapy for hematological malignancies, such as chronic lymphocytic. However, ibrutinib’s feasibility might not end there. Several other kinases with established involvement with solid malignancies (i.e., EGFR, HER2) have been found to be inhibited by this agent. Recent discoveries indicate that BTK is a potential anti-solid tumor therapy target. Consequently, ibrutinib, a BTK-inhibitor, has been studied as a therapeutic option in solid malignancies. While most preclinical studies indicate ibrutinib to be an effective therapeutic option in some specific indications, such as NSCLC and breast cancer, clinical trials contradict these observations. Nevertheless, while ibrutinib failed as a monotherapy, it might become an interesting part of a multidrug regime: not only has a synergism between ibrutinib and other compounds, such as trametinib or dactolisib, been observed in vitro, but this BTK inhibitor has also been established as a radio- and chemosensitizer. This review aims to describe the milestones in translating BTK inhibitors to solid tumors in order to understand the future potential of this agent better.

Verified
Journal Article
Open access
PDF file
Michał ZarobkiewiczMichał Zarobkiewicz
Michał Zarobkiewicz
IMIzabela Morawska
Izabela Morawska
AMAdam Grzegorz Michalski
Adam Grzegorz Michalski
JRJacek Roliński
Jacek Roliński
Agnieszka Bojarska-JunakAgnieszka Bojarska-Junak
Agnieszka Bojarska-Junak
NKT cells comprise three subsets—type I (invariant, iNKT), type II, and NKT-like cells, of which iNKT cells are the most studied subset. They are capable of rapid cytokine production after the initial stimulus, thus they may be important for polarisation of Th cells. Due to this, they may be an important cell subset in autoimmune diseases. In the current review, we are summarising results of NKT-oriented studies in major neurological autoimmune diseases—multiple sclerosis, myasthenia gravis, and Guillain-Barre syndrome and their corresponding animal models.

25 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IMIzabela Morawska
Izabela Morawska
SKSara Kurkowska
Sara Kurkowska
DBDominika Bębnowska
Dominika Bębnowska
Rafał HrynkiewiczRafał Hrynkiewicz
Rafał Hrynkiewicz
RBRafal Becht
Rafal Becht
Paulina Niedźwiedzka-RystwejPaulina Niedźwiedzka-Rystwej
Paulina Niedźwiedzka-Rystwej
Selective IgA deficiency (sIgAD) is the most common primary immunodeficiency disease (PID), with an estimated occurrence from about 1:3000 to even 1:150, depending on population. sIgAD is diagnosed in adults and children after the 4th year of age, with immunoglobulin A level below 0.07 g/L and normal levels of IgM and IgG. Usually, the disease remains undiagnosed throughout the patient’s life, due to its frequent asymptomatic course. If symptomatic, sIgAD is connected to more frequent viral and bacterial infections of upper respiratory, urinary, and gastrointestinal tracts, as well as autoimmune and allergic diseases. Interestingly, it may also be associated with other PIDs, such as IgG subclasses deficiency or specific antibodies deficiency. Rarely sIgAD can evolve to common variable immunodeficiency disease (CVID). It should also be remembered that IgA deficiency may occur in the course of other conditions or result from their treatment. It is hypothesized that allergic diseases (e.g., eczema, rhinitis, asthma) are more common in patients diagnosed with this particular PID. Selective IgA deficiency, although usually mildly symptomatic, can be difficult for clinicians. The aim of the study is to summarize the connection between selective IgA deficiency and atopic diseases.

Verified
Journal Article
Open access
PDF file
IDIzabela Dymanowska-Dyjak
Izabela Dymanowska-Dyjak
BTBarbara Terpiłowska
Barbara Terpiłowska
IMIzabela Morawska
Izabela Morawska
AMAdam Grzegorz Michalski
Adam Grzegorz Michalski
GPGrzegorz Polak
Grzegorz Polak
EGEwelina Grywalska
Ewelina Grywalska
The most common manifestation of endometriosis, a condition characterized by the presence of endometrial-like tissue outside of the uterus, is the endometrioma, a cystic ovarian lesion. It is a commonly occurring condition associated with chronic pelvic pain exacerbated prior to and during menstruation, as well as infertility. The exact pathomechanisms of the endometrioma are still not fully understood. Emerging evidence suggests a pivotal role of immune dysregulation in the pathogenesis of endometriomas, primarily influencing both local and systemic inflammatory processes. Among the factors implicated in the creation of the inflammatory milieu associated with endometriomas, alterations in both serum and local levels of several cytokines stand out, including IL-6, IL-8, and IL-1β, along with abnormalities in the innate immune system. While numerous signaling pathways have been suggested to play a role in the inflammatory process linked to endometriomas, only NF-κB has been conclusively demonstrated to be involved. Additionally, increased oxidative stress, both resulting from and contributing to endometriomas, has been identified as a primary driver of both systemic and local inflammation associated with the condition. This article reviews the current understanding of immune dysfunctions in the endometrioma and their implications for inflammation.

Verified
Journal Article
Open access
PDF file
ISIwona Smarz-Widelska
Iwona Smarz-Widelska
EGEwelina Grywalska
Ewelina Grywalska
IMIzabela Morawska
Izabela Morawska
AFAlicja Forma
Alicja Forma
AMAdam Grzegorz Michalski
Adam Grzegorz Michalski
WZWojciech Załuska
Wojciech Załuska
The continually evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in a vast number of either acute or chronic medical impairments of a pathophysiology that is not yet fully understood. SARS-CoV-2 tropism for the organs is associated with bilateral organ cross-talks as well as targeted dysfunctions, among which acute kidney injury (AKI) seems to be highly prevalent in infected patients. The need for efficient management of COVID-related AKI patients is an aspect that is still being investigated by nephrologists; however, another reason for concern is a disturbingly high proportion of various types of kidney dysfunctions in patients who have recovered from COVID-19. Even though the clinical picture of AKI and COVID-related AKI seems to be quite similar, it must be considered that regarding the latter, little is known about both the optimal management and long-term consequences. These discrepancies raise an urgent need for further research aimed at evaluating the molecular mechanisms associated with SARS-CoV-2-induced kidney damage as well as standardized management of COVID-related AKI patients. The following review presents a comprehensive and most-recent insight into the pathophysiology, clinical manifestations, recommended patient management, treatment strategies, and post-mortem findings in patients with COVID-related AKI.